In a Phase 1a/1b clinical trial, monotherapy treatment with brimarafenib resulted in a disease control rate (DCR) of 48% and an overall response rate (ORR) of 18%, with notable responses in patients with NRAS‐mutated melanoma. Here, NRAS is linked to melanoma.